New triple inhaler aims to tame uncontrolled asthma

NCT ID NCT07546981

First seen Apr 25, 2026 · Last updated May 09, 2026 · Updated 4 times

Summary

This study tests a new inhaler (CHF 5993) that combines three medicines—an anti-inflammatory, a long-acting bronchodilator, and another bronchodilator—against a standard two-medicine inhaler in Chinese adults whose asthma is not well controlled despite current treatment. About 554 participants will use one of the two inhalers for 24 weeks to see if the triple combination improves lung function and symptoms more effectively. The goal is to offer a better daily management option for people with persistent asthma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • China-Japan Friendship Hospital

    Beijing, Chaoyang District, China

  • China-Japan Friendship Hospital

    Beijing, Chaoyang District, China

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.